Literature DB >> 24847069

OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice.

Munehisa Shimamura1, Hironori Nakagami1, Mariana K Osako1, Hitomi Kurinami1, Hiroshi Koriyama1, Pang Zhengda2, Hideki Tomioka3, Akiko Tenma1, Kouji Wakayama4, Ryuichi Morishita5.   

Abstract

Osteoprotegerin (OPG) is a soluble secreted protein and a decoy receptor, which inhibits a receptor activator of nuclear factor κB (NF-κB) ligand (RANKL)/the receptor activator of NF-κB (RANK) signaling. Recent clinical studies have shown that a high-serum-OPG level is associated with unfavorable outcome in ischemic stroke, but it is unclear whether OPG is a culprit or an innocent bystander. Here we demonstrate that enhanced RANKL/RANK signaling in OPG(-/-) mice or recombinant RANKL-treated mice contributed to the reduction of infarct volume and brain edema via reduced postischemic inflammation. On the contrary, infarct volume was increased by reduced RANKL/RANK signaling in OPG(-/-) mice and WT mice treated with anti-RANKL neutralizing antibody. OPG, RANKL, and RANK mRNA were increased in the acute stage and were expressed in activated microglia and macrophages. Although enhanced RANKL/RANK signaling had no effects in glutamate, CoCl2, or H2O2-stimulated neuronal culture, enhanced RANKL/RANK signaling showed neuroprotective effects with reduced expression in inflammatory cytokines in LPS-stimulated neuron-glia mixed culture, suggesting that RANKL/RANK signaling can attenuate inflammation through a Toll-like receptor signaling pathway in microglia. Our findings propose that increased OPG could be a causal factor of reducing RANKL/RANK signaling and increasing postischemic inflammation. Thus, the OPG/RANKL/RANK axis plays critical roles in controlling inflammation in ischemic brains.

Entities:  

Keywords:  cerebral ischemia; immune cells; neuroprotection

Mesh:

Substances:

Year:  2014        PMID: 24847069      PMCID: PMC4050556          DOI: 10.1073/pnas.1400544111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.

Authors:  Naoko Yamada; Tohru Tsujimura; Haruyasu Ueda; Shin-Ichi Hayashi; Hideki Ohyama; Haruki Okamura; Nobuyuki Terada
Journal:  Cytokine       Date:  2005-08-21       Impact factor: 3.861

2.  TLR2-dependent modulation of osteoclastogenesis by Porphyromonas gingivalis through differential induction of NFATc1 and NF-kappaB.

Authors:  Ping Zhang; Jianzhong Liu; Qingan Xu; Gregory Harber; Xu Feng; Suzanne M Michalek; Jenny Katz
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

3.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Authors:  V Kartsogiannis; H Zhou; N J Horwood; R J Thomas; D K Hards; J M Quinn; P Niforas; K W Ng; T J Martin; M T Gillespie
Journal:  Bone       Date:  1999-11       Impact factor: 4.398

Review 4.  Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Authors:  S Ferrari-Lacraz; S Ferrari
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

5.  Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells.

Authors:  Karin Loser; Annette Mehling; Stefanie Loeser; Jenny Apelt; Annegret Kuhn; Stephan Grabbe; Thomas Schwarz; Josef M Penninger; Stefan Beissert
Journal:  Nat Med       Date:  2006-12-03       Impact factor: 53.440

6.  RANKL in human periapical granuloma: possible involvement in periapical bone destruction.

Authors:  R Vernal; A Dezerega; N Dutzan; A Chaparro; R León; S Chandía; A Silva; J Gamonal
Journal:  Oral Dis       Date:  2006-05       Impact factor: 3.511

7.  Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Authors:  N Udagawa; N Takahashi; H Yasuda; A Mizuno; K Itoh; Y Ueno; T Shinki; M T Gillespie; T J Martin; K Higashio; T Suda
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

8.  NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION.

Authors:  Ulf H. Lerner
Journal:  Crit Rev Oral Biol Med       Date:  2004-01-01

9.  Evaluation of pharmaceuticals with a novel 50-hour animal model of bone loss.

Authors:  Yoshiya Tomimori; Kaoru Mori; Masanori Koide; Yuko Nakamichi; Tadashi Ninomiya; Nobuyuki Udagawa; Hisataka Yasuda
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

10.  Post-ischemic inflammation in the brain.

Authors:  Takashi Shichita; Ryota Sakaguchi; Mayu Suzuki; Akihiko Yoshimura
Journal:  Front Immunol       Date:  2012-05-31       Impact factor: 7.561

View more
  41 in total

1.  Implicating Receptor Activator of NF-κB (RANK)/RANK Ligand Signalling in Microglial Responses to Toll-Like Receptor Stimuli.

Authors:  Anton Kichev; Pascale Eede; Pierre Gressens; Claire Thornton; Henrik Hagberg
Journal:  Dev Neurosci       Date:  2017-04-13       Impact factor: 2.984

2.  Poster Viewing Sessions PB01-B01 to PB03-V09.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

3.  Receptor becomes a ligand to control bone remodelling.

Authors:  Mone Zaidi; Christopher P Cardozo
Journal:  Nature       Date:  2018-09       Impact factor: 49.962

4.  Aquaporin-4 Gene Polymorphisms in Relapsing Inflammatory Optic Neuropathy and RANKL in Glioblastoma: Research and Progress on Biomarkers.

Authors:  Elif Şanli; Erdem Tüzün
Journal:  Noro Psikiyatr Ars       Date:  2021-05-27       Impact factor: 1.339

Review 5.  The role of the RANKL/RANK/OPG system in the central nervous systems (CNS).

Authors:  Reiko Hanada
Journal:  J Bone Miner Metab       Date:  2020-09-04       Impact factor: 2.626

6.  Prion infection of mouse brain reveals multiple new upregulated genes involved in neuroinflammation or signal transduction.

Authors:  James A Carroll; James F Striebel; Brent Race; Katie Phillips; Bruce Chesebro
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

7.  Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.

Authors:  Sayaka Namba; Minako Yamaoka-Tojo; Ryota Kakizaki; Teruyoshi Nemoto; Kazuhiro Fujiyoshi; Takehiro Hashikata; Lisa Kitasato; Takuya Hashimoto; Ryo Kameda; Kentaro Meguro; Takao Shimohama; Taiki Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2017-02-23       Impact factor: 2.037

8.  RANK/RANKL/OPG axis genes relation to cognitive impairment in children with transfusion-dependent thalassemia: a cross-sectional study.

Authors:  Suzan Omar Mousa; Asmaa Hosni Abd El-Hafez; Mostafa Ahmed Abu El-Ela; Mohamed Aboul-Fotouh Mourad; Rasha Nady Saleh; Samira Zain Sayed
Journal:  BMC Pediatr       Date:  2022-07-20       Impact factor: 2.567

Review 9.  Osteoimmunology: evolving concepts in bone-immune interactions in health and disease.

Authors:  Masayuki Tsukasaki; Hiroshi Takayanagi
Journal:  Nat Rev Immunol       Date:  2019-06-11       Impact factor: 53.106

Review 10.  Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review.

Authors:  Sedigheh Eskandari; Soraya Sajadimajd; Loghman Alaei; Zhaleh Soheilikhah; Hossein Derakhshankhah; Gholamreza Bahrami
Journal:  Neurotox Res       Date:  2021-06-25       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.